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Background—A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding 
occurrences. A better understanding of the molecular mechanisms leading to platelet activation is important for the 
development of improved therapies. Recently, protein tyrosine phosphatases have emerged as critical regulators of 
platelet function.
Methods and Results—This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet signaling 
and thrombosis. This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice 
displayed a selective impairment of aggregation and granule secretion mediated by the collagen receptor glycoprotein VI 
and the C-type lectin-like receptor 2. DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced 
thromboembolism compared with wild-type mice and showed severely impaired thrombus formation on ferric chloride–
induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular 
level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of phospholipase 
Cγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 
was developed. This compound specifically inhibited collagen- and C-type lectin-like receptor 2–induced human platelet 
aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells.
Conclusions—DUSP3 plays a selective and essential role in collagen- and C-type lectin-like receptor 2–mediated platelet 
activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for arterial thrombosis. This is 
the first time a protein tyrosine phosphatase, implicated in platelet signaling, has been targeted with a small-molecule 
drug.  (Circulation. 2015;131:656-668. DOI: 10.1161/CIRCULATIONAHA.114.010186.)
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Antiplatelet therapy has been effective in reducing the mortality and morbidity of acute myocardial infarction, 
the most common cause of death in developed countries.1 
However, US Food and Drug Administration–approved anti-
platelet agents have serious side effects, including gastroin-
testinal toxicity, neutropenia, thrombocytopenia, and common 
bleeding.1 There also remains a considerable incidence of 
arterial thrombosis in patients receiving currently available 
antiplatelet therapy.1 A better understanding of the molecular 
mechanisms leading to platelet activation is essential for the 
development of new therapeutics.
Clinical Perspective on p 668
Platelet activation depends on rapid phosphorylation and 
dephosphorylation of key signaling proteins, in particular 
tyrosine.2 Although the repertoire of protein tyrosine kinases 
has been well described in platelet activation, the expression, 
regulation, specificity, and function of platelet-expressed pro-
tein tyrosine phosphatases (PTPs) are largely unknown. A 
recent proteomic analysis found that 14 of 37 classic phos-
photyrosine-specific PTPs are expressed in human platelets.3 
Expression and function of the dual-specificity phospha-
tases,4,5 the largest subgroup of the PTP superfamily, are 
unexplored.
Dual-specificity phosphatase 3 (DUSP3), also known as 
Vaccinia H1–related phosphatase, is a dual-specificity phos-
phatase encoded by the DUSP3/Dusp3 gene. DUSP3 (185 
amino acids; Mr, 21 kDa), which contains only a catalytic 
(PTP) domain,6 has been reported to dephosphorylate the 
mitogen-activated protein kinases extracellular signal-reg-
ulated kinase 1/2 (ERK1/2) and Jun N-terminal kinase 1/2 
(JNK1/2).7 Additional reported substrates include epidermal 
growth factor receptor and ErbB2.8 DUSP3 is implicated in 
cell cycle regulation, and its expression is altered in human 
cancer.9–11 However, because all of these studies were per-
formed either in vitro with recombinant proteins or in cell 
lines with transient overexpression or siRNA knockdown, the 
true physiological function of DUSP3 has remained elusive. 
We recently generated a full Dusp3-knockout (Dusp3-KO) 
mouse.12 Dusp3-KO mice were healthy and fertile and showed 
no spontaneous phenotypic abnormality. However, DUSP3 
deficiency prevented neoangiogenesis and basic fibroblast 
growth factor–induced microvessel outgrowth.12 In the pres-
ent study, we identified DUSP3 as a key and nonredundant 
player in glycoprotein (GP) VI– and C-type lectin-like recep-
tor 2 (CLEC-2)–mediated signaling pathways in mouse and 
human platelets. We show that DUSP3 deficiency limits plate-
let activation and arterial thrombosis. Moreover, we developed 
a specific small-molecule inhibitor of DUSP3 that was able to 
phenocopy DUSP3 deficiency in platelets.
Methods
Platelet RNA Sampling and Microarray
Platelets from 256 healthy volunteers were isolated from citrate-anti-
coagulated blood. Donors were informed about the objectives of the 
study and signed an informed consent. The study was approved by the 
ethics committee review board of the Liège University Hospital. RNA 
extraction and microarray procedures are described in the online-only 
Data Supplement.
Mice
C57BL/6-Dusp3-KO mice were generated by homologous recombi-
nation.12 Heterozygous mice were mated to generate +/+ and −/− lit-
termates used for experimentation (male mice 8–12 weeks old). All 
experiments were approved by the local ethics committee.
Isolation of Human and Mouse Platelets
Human platelets were prepared from peripheral blood freshly drawn 
from healthy donors, as previously described.13 Mouse washed plate-
lets were prepared as previously described.14
Isolation of Human and Murine B and T Cells
Human B and T cells were sorted from freshly collected blood with 
the use of EasySep B and T cell–negative selection kits (Stemcell 
Technologies). Mouse B and T cells were sorted from spleens.
Platelet Aggregation Analyses
Light transmission was recorded during platelet aggregation induced 
by collagen, convulxin, collagen-related peptide (CRP), rhodocytin, 
thrombin, U46619, or ADP in the presence of 2 mmol/L CaCl
2
 on a 
Lumi-Aggregometer (Chrono-log).
Flow Cytometry
Washed platelets were stimulated for 15 minutes with different con-
centrations of collagen, CRP, thrombin, or ADP under nonstirring con-
ditions. Saturating concentrations of FITC-conjugated P-selectin and 
phycoerythrin-conjugated JON/A antibodies were added. Samples 



































































































































Figure 1. Dual-specificity phosphatase 3 (DUSP3) expression 
in human and mouse platelets. A, Microarray data of mRNA 
expression of 17 atypical dual-specificity phosphatases (DSPs) in 
human platelets isolated from 256 healthy volunteers. Each open 
circle represents 1 individual. DNM3 was used as positive control 
for platelet-expressed mRNA. Data are presented as ratio of 
the fluorescence intensity for the DSP probe of interest and the 
mean fluorescence intensity for the housekeeping genes of each 
sample. A negative value corresponds to an expression below 
background level. Mean±SEM values are shown. B through  
D, DUSP3 protein expression in human B and T lymphocytes 
and in platelets isolated from peripheral blood (B), in mouse 
splenic B and T cells and in washed platelets (C), and in  
wild-type (WT) and Dusp3-knockout (KO) mouse washed 
platelets (D). Western blot analysis was performed with  
anti-human (B) and anti-mouse DUSP3 (C and D). GAPDH was 
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Electron Microscopy
Platelet pellets were fixed for 60 minutes in 2.5% glutaralde-
hyde in Sörensen buffer (0.1 mol/L, pH 7.4), postfixed for 30 
minutes with 1% osmium tetroxide, dehydrated in a series of 
ethanol concentrations, and embedded in Epon. Ultrathin sec-
tions were stained with uranyl acetate and lead citrate and 






































































































Figure 2. Dual-specificity phosphatase 3 (DUSP3)–deficient platelets exhibit impaired glycoprotein (GP) VI– and C-type lectin-like 
receptor 2 (CLEC-2)–mediated platelet aggregation. A through E, Washed platelets prepared from wild-type (WT) or Dusp3-knockout (KO) 
mice were stimulated with collagen (0.5 and 1 μg/mL; A), collagen-related peptide (CRP; 0.1, 0.3, and 1 μg/mL; B), convulxin (CVX; 5, 10, 
and 100 ng/mL; C), rhodocytin (2.5, 5, and 10 nmol/L; D), or the thromboxane A2 analog U46619 (1 μmol/L), thrombin (0.05 U/mL), or ADP 
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Whole-Blood Platelet Aggregate Formation  
Under Flow
Thrombus formation under flow conditions was assessed with anticoagu-
lated mouse blood (4 U/mL heparin, 20 μmol/L PPACK), as previously 
described.15 Area coverage from phase-contrast images was analyzed 
with ImagePro (Media Cybernetics).16 Area coverage by platelets stained 
with OG488-annexin A5 was determined with Quanticell (Visitech).
Ca2+ Flux
Apyrase (0.5 U/mL)-treated murine washed platelets were loaded with 
3.5 μmol/L fura-2-acetoxymethyl ester in the presence of Pluronic 
F-127 for 15 minutes. Fluorescence was recorded on an Aminco spec-
trofluorimeter (SLM Instruments), as described elsewhere.17
Arterial Thrombosis Models
Pulmonary embolism was induced by injection of a mixture of col-
lagen (170 μg/kg) and epinephrine (60 μg/kg) into the plexus retro-
orbital veins of anesthetized mice (ketamine, 60 mg/kg; xylazine, 5 
mg/kg). Time to death was monitored. Lungs were perfused with 4% 
formaldehyde solution and collected for histological studies.
Injury of carotid arteries of anesthetized mice was performed by 
applying a filter paper soaked in 10% ferric chloride (FeCl
3
) solu-
tion to the exposed artery for 5 minutes.18 Fluorescence of exog-
enously carboxyfluorescein succinimidyl ester–labeled platelets 
was monitored with a BX61WI microscope (Olympus). Digital 
images were captured with a Hamamatsu 9100-13 electron-mul-
tiplying charge-coupled device camera using a Lambda DG-4 
(Sutter instrument) light source and Slidebook software 5.5 (3i).
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Figure 3. Impaired glycoprotein (GP) VI–mediated platelet activation in dual-specificity phosphatase 3 (DUSP3)–deficient platelets. A and 
B, Washed platelets from wild-type (WT) or Dusp3-knockout (KO) mice were stimulated with 0.1, 0.3, or 1 μg/mL collagen-related peptide 
(CRP) or 0.5 or 1 μg/mL collagen under nonstirring conditions or left untreated. Surface expression of P-selectin and active integrin αIIbβ3 
(JON/A) was quantified by flow cytometry. Mean fluorescence intensity (MFI) histograms for p-selectin (A) and JON/A (B) are shown. Data 
were analyzed with ANOVA and the Bonferroni multiple-comparison test and represent the mean±SEM of 4 independent experiments 
performed on platelet pools from 3 mice each; *P<0.05, **P<0.01. C, Electron microscopy analysis of WT and Dusp3-KO washed 
platelets. Platelet ultrastructure was visualized in the resting state or on convulxin stimulation (100 ng/mL). D, Scatterplots of α- and 
dense granules counted on 5 separate micrographs. Data were analyzed with the unpaired Student t test and represent the mean±SEM of 
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Mouse Irradiation and Bone Marrow 
Transplantation
Donor mice (7–8 weeks old) were euthanized by cervical disloca-
tion. Tibia and fibula were collected, and bone marrow was flushed 
with PBS. Then, 10×106 single bone marrow cells were transplanted 
to 4- to 5-week-old lethally irradiated (866.3 cGy) recipient mice. 
Chimeric mice were used in the FeCl
3
 model 3 to 4 weeks after trans-
plantation. Chimerism was evaluated by Western blot of DUSP3 in 
lysates of peritoneal cavity cells.
Tail Bleeding
Mice were anesthetized with isoflurane. A 3-mm portion of the tail 
tip was excised and submerged in a 37°C water bath. Bleeding was 
monitored for 15 minutes.
Platelet Activation, Cell Lysis, Immunoprecipitation, 
and Western Blotting
Mouse washed platelets were activated with CRP or rhodocytin in 
Tyrode buffer for 30, 60, or 90 seconds under 400-rpm stirring condi-
tions at 37°C. Western blotting and immunoprecipitations were per-
formed according to standard procedures.19
Statistical Analysis
Data are presented as mean±SEM of at least 3 independent experi-
ments. Data were analyzed by use of the unpaired Student t test or 
ANOVA and the Bonferroni multiple-comparison test, as indicated 
in each figure legend. Differences in survival were determined with 
Kaplan-Meier analysis (log-rank Mantel test). Values of P<0.05 were 
considered significant. Calculations were performed with GraphPad-
Prism (GraphPad Software, Inc).
Results
DUSP3 Expression in Platelets
Transcriptomic analysis of platelets from 256 healthy 
human individuals revealed that DUSP3-encoding mRNA 
is highly expressed in platelets (Figure 1A). An abundance 
of DUSP3 in human and mouse platelets was confirmed 
by Western blot analysis (Figure 1B and 1C). Expression 
levels of DUSP3 were substantially higher in platelets 
compared with B and T lymphocytes (Figure 1B and 1C); 
DUSP3 function in B and T lymphocytes has previously 
been described.7 Thus, we set out to investigate the role of 
DUSP3 in platelets using both genetic deletion in mice and 
pharmacological inhibition of DUSP3 in isolated human 
platelets.
Activation and Aggregation of DUSP3-Deficient 
Mouse Platelets
Using our previously generated Dusp3-KO mice,12 we 
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Figure 4. Dual-specificity phosphatase 3 (DUSP3) 
deficiency impairs Syk tyrosine phosphorylation. 
Total lysates (TLs) were prepared from wild-type 
(WT) or Dusp3-knockout (KO) mice platelets. Cells 
were nonactivated or activated by collagen-related 
peptide (CRP; 0.3 μg/mL) or rhodocytin  
(10 nmol/L) for 30, 60, or 90 seconds. A through 
C, Western blot analysis with anti-phosphotyrosine 
(pY) antibody (4G10) and with extracellular signal-
regulated kinase 1/2 (ERK1/2; A) or GAPDH (C) 
as loading control. Arrows in B indicate unknown 
protein bands with attenuated pY levels in DUSP3-
deficient platelets. D and E, Representative pY blot 
of Syk immunoprecipitates (IPs) from TLs of CRP-
activated (D) or rhodocytin-activated (E) platelets.  
F and G, Representative blot of Syk 
phosphorylation on Tyr-323 and Tyr-525/526 in 
CRP-activated (F) or rhodocytin-activated (G) 
platelets. Normalization was performed with 
total Syk. H, pY and Syk Western blots on Fc 
receptor γ-chain (FcRγ) IPs. I and J, pY blot of 
phospholipase Cγ2 (PLCγ2) IPs from TLs of CRP-
activated (I) or rhodocytin-activated (J) platelets. 
Results shown are representative of 3 independent 
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not express DUSP3 (Figure 1D). Hematologic parameters 
were normal except for slight but significant differences in 
monocytes (P<0.05) and mean platelet volume (P<0.0001; 
Table I in the online-only Data Supplement). Dusp3-KO 
mice did not show any spontaneous bleeding or throm-
botic disorders. However, in platelet aggregation assays, 
DUSP3-deficient platelets failed to aggregate in response 
to low concentrations of collagen (0.5 μg/mL) and selec-
tive GPVI agonists, including convulxin (5 ng/mL) and 
CRP (0.1 μg/mL; Figure 2A–2C). Additionally, Dusp3-KO 
platelets exhibited delayed aggregation induced by low 
concentrations of rhodocytin (2.5 and 5 nmol/L), a selec-
tive CLEC-2 receptor agonist (Figure 2D). GPVI and 
CLEC-2 surface expression on Dusp3-KO platelets was 
similar to that of wild-type (WT) platelets (Figures IA 
and IIA in the online-only Data Supplement). In contrast, 
aggregation induced by ADP (5–50 μmol/L), the throm-
boxane A
2
 mimetic U46619 (0.75–2 μmol/L), or thrombin 
(0.01–0.1 U/mL) occurred normally (Figure 2E and data 
not shown), indicating normal G-protein–coupled recep-
tor–mediated responses.
To investigate the mechanism responsible for the impair-
ment of collagen- and CRP-induced aggregation of DUSP3-
deficient platelets, we analyzed their ability to release 
granule content by measuring P-selectin surface expression, 





using the JON/A antibody, which is specific for the high-




. In DUSP3-deficient 
compared with WT platelets, P-selectin expression was 
reduced after stimulation with a low concentration of col-
lagen (0.5 μg/mL) or various concentrations of CRP (0.1, 






























































































Figure 5. Impaired platelet aggregate formation on whole blood from dual-specificity phosphatase 3 (DUSP3)–deficient mice. A through 
D, Anticoagulated blood from wild-type (WT) or Dusp3-knockout (KO) mice was perfused over a collagen-coated coverslip through a 
parallel-plate transparent flow chamber at a wall shear rate of 1000 seconds-1 for 4 minutes. Representative phase-contrast images of 
fixed platelets (A) and percentages of surface coverage by platelets (B) are shown. Exposure of phosphatidylserine (PS) was detected 
by postperfusion with heparin and OG488-labeled Annexin-V–containing rinsing buffer. Representative fluorescent images (C) and 
percentage of area coverage by labeled platelets (D) are shown. E and F, Intracellular Ca2+ increase in WT and Dusp3-KO platelets 
on convulxin stimulation (50 ng/mL). Representative curves (E) and histogram depicting the area under the curve (F) are shown. WT 
values are arbitrarily set to 100%. An unpaired Student t test was used for comparison. Results are representative of 5 independent 
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was reduced with low concentrations of collagen (0.5 μg/
mL) and CRP (0.1 μg/mL; Figure 3B). Electron micros-
copy analysis of resting DUSP3-deficient platelets revealed 
normal ultrastructure but a slightly increased number of 
α-granules (Figure 3C and 3D). When activated with con-
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Figure 6. Impaired arterial thrombosis and preserved hemostasis in dual-specificity phosphatase 3 (DUSP3)–deficient mice. A through 
C, Pulmonary thromboembolism induced by injection of a mixture of collagen and epinephrine. Mortality incidence rates compared by 
use of Kaplan-Meir analysis with a log-rank test (n=20 for Dusp3-knockout [KO] and n=23 for wild-type [WT] mice; A), quantification 
of the number of occluded vessels per visual field on lung sections from WT and Dusp3-KO mice (B), and representative field on lung 
sections from WT and Dusp3-KO mice (C) are shown. Data (from 3 to 6 lung sections from 3 mice from each group) were analyzed 
by use of an unpaired Student t test; **P<0.01. D and E, FeCl3 injury of carotid arteries. Representative snapshot images in WT and 
Dusp3-KO mice (D) and in WT mice transplanted with WT (WT>WT) or with Dusp3-KO (KO>WT) bone marrow (BM) cells (E) are shown. 
F, Western blot analysis of DUSP3 expression in peritoneal total lysates from WT>WT and KO>WT BM-transplanted mice used in the 
FeCl3 assay. Normalization was performed with GAPDH. G, Numbers of intact and partially occluded vessels are shown for 4 mice from 





 http://ahajournals.org by on Septem
ber 15, 2021
Musumeci et al  DUSP3, a New Player in Arterial Thrombosis  663
DUSP3-deficient platelet aggregates compared with WT 
(Figure 3C). These findings indicate that DUSP3 deficiency 
impairs GPVI- and CLEC-2–dependent mouse platelet acti-
vation and aggregation.
GPVI and CLEC-2 Signaling in DUSP3-Deficient 
Platelets
Earlier studies suggested that DUSP3 dephosphorylates 
ERK1/2 and JNK1/2 but not p38.7 Therefore, we evaluated 
MLS-0437605DMSO







































































































































































































































































Figure 7. The dual-specificity phosphatase 3 (DUSP3)–specific inhibitor MLS-0437605 inhibits platelet activation in response to collagen-related 
peptide (CRP) and rhodocytin. A, Chemical structure and key properties of MLS-0437605. B through D, Washed human platelets (B and C) or wild-
type (WT) and Dusp3-knockout (KO) mouse washed platelets (D) were preincubated for 30 minutes with dimethyl sulfoxide (DMSO; vehicle) or with 
MLS-0437605 (3.7 μmol/L) before being stimulated with CRP (0.5 μg/mL), rhodocytin (5 or 10 nmol/L), or U46619 (0.15 μg/mL). Representative 
platelet aggregation curves (B and D) and quantification of platelet aggregation from 3 healthy human donors (C) are shown. Results were analyzed 
by use of 1-way ANOVA and the Bonferroni multiple-comparison test and are presented as mean±SEM; **P<0.01. E through J, Total lysates 
(TLs) were prepared from vehicle- or MLS-0437605–pretreated human platelets. Cells were nonactivated or activated with CRP or rhodocytin for 
the indicated times. Western blot analysis was performed with 4G10 antibody for global phosphotyrosine of CRP (E) and rhodocytin (F) activated 
platelets. Extracellular signal-regulated kinase 1/2 (ERK1/2) was used as a loading control. G and H, Representative phosphotyrosine (pY) blot of Syk 
immunoprecipitates (IPs) from TLs of CRP-activated (G) or rhodocytin-activated (H) platelets. I and J, pY blot of phospholipase Cγ2 (PLCγ2) IPs from 
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the activation of these mitogen-activated protein kinases 
using phospho-specific antibodies at basal levels and after 
CRP stimulation. No differences in mitogen-activated pro-
tein kinase activation between DUSP3-deficient and WT 
platelets were found (Figure III in the online-only Data 
Supplement). We then analyzed global tyrosine phosphoryla-
tion and found decreased phosphorylation of a ≈70-kDa band 
in DUSP3-deficient compared with WT platelets after CRP 
or rhodocytin stimulation (Figure 4A and 4C). Longer expo-
sure of the phosphotyrosine blot revealed additional bands 
(at ≈12, ≈26, and ≈40 kDa) with decreased phosphorylation 
in DUSP3-deficient compared with WT platelets after CRP 
stimulation (Figure 4B). We then tested whether the observed 
change in phosphotyrosine of the ≈70-kDa band may cor-
respond to phosphotyrosine levels in the tyrosine kinase 
Syk (Mr, 72.1 kDa), a key signaling molecule in GPVI- and 
CLEC-2–mediated platelet activation. Indeed, phosphotyro-
sine of immunoprecipitated Syk was significantly reduced in 
DUSP3-deficient compared with WT platelets after GPVI and 
CLEC-2 stimulation (P<0.05; Figure 4D and 4E and Figure 
IVA and IVB in the online-only Data Supplement). Probing 
total lysates of DUSP3-deficient or WT platelets with phos-
pho-Syk–specific antibodies revealed that, after activation 
with CRP, Syk phosphorylation was reduced on the activa-
tory residues Tyr-525/526, whereas phosphorylation of the 
negative regulatory Tyr-323 was not affected (Figure 4F and 
Figure IVF and IVG in the online-only Data Supplement). 
In rhodocytin-stimulated platelets, Syk phosphorylation was 
reduced on both Tyr-525/526 and Tyr-323 in the absence of 
DUSP3 (Figure 4G and Figure VH and VI in the online-only 
Data Supplement).
Syk is recruited to the GPVI/Fc receptor γ-chain (FcRγ) 
complex via phosphorylation of FcRγ-associated immu-
noreceptor tyrosine-based activation motifs by Src-family 
kinases (SFKs) and is then activated via autophosphoryla-
tion.20,21 We found that phosphorylation of FcRγ-associated 
immunoreceptor tyrosine-based activation motifs was 
reduced in DUSP3-deficient compared with WT plate-
lets in response to CRP (Figure 4H and Figure IVJ in the 
online-only Data Supplement). In agreement with this 
observation, recruitment of Syk to FcRγ was impaired in 
DUSP3-deficient platelets (Figure 4H and Figure IVK in 
the online-only Data Supplement). Additionally, inducible 
tyrosine phosphorylation in phospholipase Cγ2, a key sig-
naling molecule downstream of Syk, was reduced in both 
CRP- and rhodocytin-stimulated DUSP3-deficient compared 
with WT platelets (Figures 4I and 4J and Figure IVL and 
IVM in the online-only Data Supplement). In contrast, acti-
vation of SFKs, including Lyn, Fyn, and Src, was not altered 
(Figure VA and VB in the online-only Data Supplement), 
indicating that the reduced activation and recruitment of Syk 
in DUSP3-deficient platelets was not attributable to aberrant 
activation of SFKs.
Collagen-Induced Aggregation Under Flow, 
Calcium Fluxes, and Phosphatidylserine Exposure 
in DUSP3-Deficient Platelets
To further assess the role of DUSP3 in GPVI-dependent 
platelet responses, platelet aggregate formation and exposure 
of procoagulant phosphatidylserine on a collagen surface 
were analyzed in whole mouse blood under flow. The area 
covered by platelets was reduced by ≈40% for blood from 
Dusp3-KO compared with WT mice (Figure 5A and 5B), 
which was in agreement with reduced GPVI activation in 
DUSP3-deficient platelets.22 Accordingly, overall phosphati-
dylserine exposure on adhered platelets was also diminished 
(Figure 5C and 5D). Because phosphatidylserine exposure 
requires Ca2+ influx,23 we investigated whether Ca2+ flux 
was affected by DUSP3 deficiency. Convulxin-induced Ca2+ 
flux was greatly reduced (50%) in DUSP3-deficient com-
pared with WT platelets (Figure 5E and 5F). Thapsigargin-
induced Ca2+ increase occurred normally in DUSP3-deficient 
platelets (Figure VIA in the online-only Data Supplement), 
suggesting intact intrinsic Orai 1–mediated store-operated 
Ca2+ entry. Additionally, there were no differences in Ca2+ 
increases induced by thrombin, ADP, or U46619 between WT 
and Dusp3-KO platelets (Figure VIB–VID in the online-only 
Data Supplement). These data further support a positive role 
of DUSP3 in GPVI-mediated platelet activation under physi-
ological flow conditions.
DUSP3 Deficiency and Thrombus Formation  
In Vivo
To evaluate the importance of DUSP3 in platelet func-
tion in vivo, we used a model of pulmonary thromboem-
bolism induced by intravenous injection of a mixture of 
collagen and epinephrine. About 80% of DUSP3-deficient 
compared with 45% of WT mice survived (Figure 6A). 
Analyses of lung sections revealed significantly decreased 
numbers of occluded microvessels in DUSP3-deficient 
compared with WT mice (P<0.001; Figure 6B and 6C). 
We then examined thrombus formation in real time by 
intravital microscopy in a model of FeCl
3
-induced injury 
of the carotid arteries. In this model, collagen is exposed 
to circulating blood, and thrombus formation depends 
highly on GPVI. In DUSP3-deficient mice, blood vessels 
were never occluded as a result of failure to form stable 
thrombi, whereas full occlusion occurred at 8 to 10 min-
utes after FeCl
3
 application in WT vessels (Figure 6D and 
6G). To test whether the defect in thrombus formation was 
due specifically to impaired platelet function, we gener-
ated chimeric mice by transferring Dusp3-KO bone mar-
row (KO>WT) or WT bone marrow (WT>WT) to lethally 
irradiated WT mice. Successful transplantation was evalu-
ated by quantification of DUSP3 expression in peritoneal 
cell lysates from KO>WT and WT>WT mice (Figure 6F). 
Similar to Dusp3-KO, we found that thrombus formation 
was severely impaired in blood vessels of KO>WT mice 
(Figure 6E and 6G), confirming that the thrombosis defect 
in DUSP3-deficient animals was attributable to platelet 
dysfunction. Importantly, tail bleeding time, a measure 
of primary hemostasis in vivo, was identical for WT and 
DUSP3-deficient mice (Figure 6H).
Pharmacological Inhibition of DUSP3
To corroborate DUSP3 function in human platelets, we 
investigated the possibility of specifically inhibiting DUSP3 
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we used high-throughput screening, with a colorimetric 
phosphatase assay with p-nitrophenolphosphate as sub-
strate, and screened 291 018 drug-like molecules.24 Of the 
1524 primary high-throughput screening hits (≥50% inhibi-
tion), 1048 compounds were available from BioFocus DPI 
and ordered for confirmatory assays. The hits were tested 
in 2 reconfirmation single-dose screens in triplicate with the 
use of both the primary colorimetric assay and an orthogo-
nal fluorescent assay with 3-O-methylfluorescein phosphate 
as substrate. Compounds with an average of ≥50% inhibi-
tion of DUSP3 activity were further tested in a 10-point 
dose-response assay in both colorimetric and fluorescent 
formats. IC
50
 values were determined, and 67 “cross-active” 
compounds were identified with IC
50
 values <20 μmol/L in 
both assays. On visual inspection of each molecule, 32 com-
pounds were discarded from further consideration because 
of their known promiscuous PTP inhibitory activity. The 
remaining 35 compounds were taken into selectivity profil-
ing studies for further prioritization. Compound selectivity 
for inhibiting DUSP3 over the related DUSP6 and 3 addi-
tional PTPs, HePTP, LYP, and STEP, was evaluated (Table II 
in the online-only Data Supplement).
On the basis of the selectivity and potency of compounds, 
2 scaffolds were selected for structure-activity relationship 
studies: MLS-0103602 and MLS-0049585 (Table II in the 
online-only Data Supplement). MLS-0103602 (IC
50
=0.37 
μmol/L) was the most potent inhibitor with some degree of 
selectivity for DUSP3; MLS-0049585 (IC
50
=2.68 μmol/L) 
exhibited the best selectivity for DUSP3. On the basis of 
the benzothioamide structure of MLS-0103602, 37 analogs 
were tested and counterscreened. All analogs were at least 
an order of magnitude less potent than the original hit, with 
no improvement in selectivity, leading to the termination 
of this series (data not shown). In contrast, several analogs 
containing the N-(benzo[d]thiazol-2-yl)-5-phenyl-1,3,4-
oxadiazol-2-amine structure of MLS-0049585 with simi-
lar or even better potency could be identified (Table III 
in the online-only Data Supplement). The 4 most potent 
compounds were selected for testing in human platelets. 
Inhibition of platelet aggregation was assessed with plate-
lets collected from 3 healthy donors. In these experiments, 
MLS-0437605 (Figure 7A) efficiently inhibited platelet 
aggregation in response to CRP and rhodocytin, but not after 
stimulation with thromboxane (Figure 7B and 7C). Tests on 
platelets from WT mice yielded similar results (Figure 7D). 
In contrast, MLS-0437605 only minimally affected the 
aggregation of DUSP3-deficient platelets (Figure 7D). 
Selectivity was further evaluated against 10 additional 
PTPs (Table). In these assays, MLS-0437605 showed excel-
lent selectivity for DUSP3 over the vast majority of PTPs 
tested. Importantly, there was good selectivity of MLS-
0437605 for DUSP3 over DUSP22 (7-fold), another dual-
specificity phosphatase that is highly expressed in platelets 
(Figure 1A). We next examined the effect of MLS-0437605 
on GPVI- and CLEC-2–induced signaling in human plate-
lets. Global tyrosine phosphorylation was analyzed on total 
lysates from resting or activated platelets. MLS-0437605 
caused a decrease in phosphotyrosine of an ≈70-kDa band 
after stimulation with CRP or rhodocytin (Figure 7E and 
7F). Tyrosine phosphorylation of immunoprecipitated Syk 
and PLCγ2 was also reduced by MLS-0437605 (Figure 7G 
and 7H). These data demonstrate that pharmacological inhi-
bition of DUSP3 activity in human platelets affects plate-
let signaling in a manner similar to DUSP3 deficiency in 
Dusp3-KO platelets.
Discussion
This is the first study implicating a member of the PTP 
subfamily of dual-specificity phosphatases in GPVI- and 
CLEC-2–induced signaling. Motivated by our finding that 
DUSP3 is highly expressed in human and mouse platelets, 
we used Dusp3-KO mice to study the role of this phospha-
tase in hemostasis and thrombosis. DUSP3-deficient mice 
were more resistant to pulmonary thromboembolism than 
their WT littermates. Thrombus formation was strongly 
impaired in the model of FeCl
3
-induced injury of carotid 
artery in a platelet-specific manner. Intriguingly, DUSP3-
deficient mice did not bleed spontaneously and showed nor-
mal tail bleeding times. These findings suggest that DUSP3 
plays a key role in arterial thrombosis but is dispensable for 
primary hemostasis.
Ex vivo, on platelet stimulation with a low concentration of 
collagen, convulxin, CRP, or rhodocytin, DUSP3 deficiency 





 inside-out activation. In contrast, plate-
let activation mediated by G-protein–coupled receptor ago-
nists was not affected. DUSP3 deficiency led to a reduction 
in thrombus formation on collagen-coated surfaces under 
arterial shear, as well as lower phosphatidylserine exposure 
at the surface of adhered platelets. These data indicate that 
GPVI- and CLEC-2–mediated platelet activation is impaired 
in DUSP3-deficient platelets.25–27 DUSP3 was dispens-




 outside-in signaling, as indicated by 
unaltered fibrin clot retraction (data not shown). Dusp3-KO 
mice exhibited levels of thrombus formation comparable to 
the previously reported GPVI-KO/FcRγ-KO,28–30 CLEC-2–
KO,31 CLEC-2–depleted,26 GPVI-depleted,32 and CLEC-2/
GPVI–depleted mice.27 Similar to our findings in DUSP3-
deficient mice, GPVI-KO and CLEC-2–KO mice do not 
exhibit prolonged bleeding time.28,31,33 DUSP3-deficient mice 
were also protected against pulmonary thromboembolism 
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induced by a mixture of collagen and epinephrine, similar to 
GPVI-KO mice.33
At the molecular level, phosphorylation of the previously 
reported DUSP3 substrates ERK1/2 and JNK1/27 was not 
affected by DUSP3 deficiency, suggesting that signaling 
defects in DUSP3-deficient platelets are independent of the 
ERK1/2 and JNK1/2 pathways. However, we cannot exclude 
the possibility of functional or compensatory redundancies 
between DUSP3 and other phosphatases.
GPVI and CLEC-2 signaling pathways share many simi-
larities, including the activation of Syk, phospholipase Cγ2, 
and adapter proteins such as LAT and SLP-76.34 However, 
there is also a significant difference: in GPVI-stimulated 
platelets, SFKs initiate signaling through phosphorylation 
of the FcRγ-associated immunoreceptor tyrosine-based acti-
vation motifs, leading to binding and activation of Syk.20,21 
In contrast, signaling through CLEC-2 depends on phos-
phorylation of CLEC-2 by Syk in an SFK-independent man-
ner.35 Because DUSP3 deficiency limits platelet activation in 
response to both GPVI and CLEC-2 stimulation, SFK func-
tion is likely not controlled by DUSP3, which is also sup-
ported by our data showing that phosphotyrosine in SFKs is 
not altered in Dusp3-KO platelets. On the contrary, Syk may 
be directly or indirectly targeted by DUSP3. Intriguingly, 
however, DUSP3 deficiency decreased phosphotyrosine lev-
els in Syk. Furthermore, no hyperphosphorylated protein 
could be identified in phosphotyrosine blots of total lysates 
from DUSP3-deficient platelets. This raises the question of 
whether phosphoserine or phosphothreonine in Syk or other 
protein(s) may be targeted by DUSP3, a dual-specificity 
phosphatase able to dephosphorylate both phosphotyrosine 
and phosphoserine/phosphothreonine. Given the limited 
recognition sites of available phosphoserine/phosphothreo-
nine antibodies, future studies using quantitative phospho-
proteomics analysis are necessary to address this question.
Platelet binding to von Willebrand factor via GPIbα 





, leading to platelet arrest and subsequent platelet 
thrombus formation. The von Willebrand factor–GPIb 
axis also induces GPVI dimerization, resulting in direct 
enhancement of GPVI interaction with collagen.36 However, 
platelets from Dusp3-KO mice exhibit normal binding to 
von Willebrand factor–coated surface under flow (Figure 
VII in the online-only Data Supplement), suggesting intact 
GPIb signaling in these animals. Interestingly, a recent 
study by Nieswandt’s group showed that combined deple-
tion of GPVI and CLEC-2 was sufficient to abrogate arterial 
thrombosis in mice.27 Thus, the defects observed in DUSP3-
deficient platelets on CLEC-2– and GPVI-induced signaling 
are sufficient to explain the impaired thrombus formation in 
Dusp3-KO mice.
Finally, platelets are anucleate cells that are not amenable 
to RNA interference or recombinant DNA technologies. Thus, 
to corroborate our findings in human cells, we used a chemi-
cal genomics approach. Specifically, a small-molecule inhibi-
tor of DUSP3 was identified via high-throughput screening 
of a large chemical library and subsequent structure-activity 
relationship studies. Previously reported DUSP3 inhibitors 
suffer from poor selectivity, lack of efficacy, or both,37–41 or 
they cause immediate spontaneous aggregation of platelets 
(data not shown).42 Thus, we developed a novel, specific, and 
efficacious inhibitor that we used to inhibit DUSP3 function 
in human washed platelets. Similar to DUSP3 deficiency in 
murine cells, inhibition of DUSP3 activity in human plate-
lets led to suppression of platelet aggregation, specifically in 
response to CRP and rhodocytin, but not in response to the 
G-protein–coupled receptor agonist thromboxane. MLS-
0437605 is a drug-like compound43 and may serve as the 
basis for the development of potential therapeutics targeting 
DUSP3 for the treatment of arterial thrombosis.
Conclusions
We demonstrated that DUSP3 is a key signaling molecule for 
GPVI- and CLEC-2–induced platelet activation. We devel-
oped a specific small-molecule inhibitor of DUSP3 that effi-
ciently inhibited human platelet activation in vitro. Given that 
Dusp3-KO mice remain healthy, do not exhibit any sponta-
neous phenotype, and do not suffer from increased bleeding 
events, our findings may lead to a novel antiplatelet therapy.
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CLINICAL PERSPECTIVE
A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. The 
present study demonstrates that dual-specificity phosphatase 3 (DUSP3) phosphatase deficiency in mice does not cause 
bleeding but still protects against arterial thrombosis and collagen-induced thromboembolism. This protection is at least 
partially attributable to the selective inhibition of glycoprotein VI– and C-type lectin-like receptor 2–dependent signaling. 
Furthermore, ex vivo, a selective inhibitor of DUSP3 limits glycoprotein VI– and C-type lectin-like receptor 2–mediated 
aggregation of human platelets. Our findings pave the way for further preclinical studies in animal models and future valida-
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